• University of Missouri-Columbia (2019)

  • Molecular Genetics and Genomics

  • David T. Curiel, MD, PhD

  • Adenoviral gene therapy for MPS I

  • s.hurt@wustl.edu


MPS I is a lysosomal storage disease that is caused by a genetic defect in the IDUA gene with limited treatment options. I am attempting to develop a treatment for MPS I using adenoviral vectors to deliver CRISPR/Cas9 and replace the malfunctioning gene.

Graduate Publications:

Hurt SC, Dickson PI, Curiel DT. 2021 Mucopolysaccharidoses type I gene therapy. J Inherit Metab Dis, 44(5):1088-98.

Last Updated: 6/24/2020 10:18:06 AM

Back To Top

Follow us: